- Vienna '18
- Athens 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
First Author: G.Shemesh ISRAEL
Co Author(s): E. Rosenfeld S. Kurtz M. Lazar S. Kivity S. Langier
Back to previous
To evaluate the type of hypersensitivity reaction induced by Brimonidine 0.5%, Timolol 0.2%, and its combination using the basophil activation test (Basotest) in patients who had a hypersensitivity reaction to Brimonidine 0.5% and compared them to healthy individuals.
ṗ Department of Ophthalmology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Ġ Allergy and Immunology Internal Medicine Division, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Peripheral blood was drawn from eight patients with a proven hypersensitivity to Brimonidine, and 6 healthy individuals. Basophil activation was identified by the expression of the activation molecule CD63 in high IgE cells (CD63+IgE high+). Basophil activation was tested following exposure to either Brimonidine, Timolol or its combination (combigan).
In healthy individuals there was a statistically significant difference in the percentage of CD63 activation when comparing Combigan (0.87%) to Timolol (2.27%), (p= 0.012) and Combigan (0.87%) to Alphagan (2.58%) (p=0.017). In the hypersensitive group, statistical significance was also found when comparing Combigan (0.81%) to Timolol (1.84%) (p=0.043), and almost statistical significance between Combigan (0.81%) to Alphagan (2.45%) (p=0.068).
Based on the suppression of basophil activation drawn from both patients with a known hypersensitivity to Brimonidine, and healthy individuals, it is proposed that ß-blockers clinical effect is most likely pharmacological or physiological.